advertisement
11.3.3 Apraclonidine, brimonidine (9)
Showing records 1 to 9
Display all abstracts in classification 11.3.3 Apraclonidine, brimonidine
Search within classification 11.3.3 Apraclonidine, brimonidine91466 Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model
Rodrigo MJ
Biomaterials science 2020; 8: 6246-6260
91036 Brimonidine-associated uveitis - a descriptive case series
Hopf S
BMC Ophthalmology 2020; 20: 489
91466 Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model
Rodrigo MJ
Biomaterials science 2020; 8: 6246-6260
91036 Brimonidine-associated uveitis - a descriptive case series
Mercieca K
BMC Ophthalmology 2020; 20: 489
91466 Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model
Cardiel MJ
Biomaterials science 2020; 8: 6246-6260
91036 Brimonidine-associated uveitis - a descriptive case series
Pfeiffer N
BMC Ophthalmology 2020; 20: 489
91466 Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model
Fraile JM; Mendez-Martinez S; Mendez-Martinez S
Biomaterials science 2020; 8: 6246-6260
91036 Brimonidine-associated uveitis - a descriptive case series
Prokosch-Willing V
BMC Ophthalmology 2020; 20: 489
91466 Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model
Martinez-Rincon T; Martinez-Rincon T; Subias M; Subias M; Polo V; Ruberte J; Ramirez T; Vispe E; Luna C; Mayoral JA; Garcia-Martin E
Biomaterials science 2020; 8: 6246-6260